Progress has been shown in the death rates from prostate cancer and the other three leading cancers-lung, breast, and colorectal. Deaths from prostate cancer have fallen 4.0% during the 5-year period from 1996 to 2000. Bladder cancer decreased by 0.4% over the same period.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.